IBI-Tech and Peixe Rosa Program Strategic Partnership to Advance Biotech Collaboration Between Israel and Brazil
This release is a segment of a full release published here. Strengthening Ties Between Israel and Brazil in Life Sciences and R&D IBI-Tech has formally expressed its commitment to collaborating with the Peixe Rosa Program to bridge Israel’s cutting-edge biotech innovation with Brazil’s expanding life sciences sector. With over a decade of experience connecting Israel’s R&D capabilities with the Brazilian market, IBI-Tech aims to enhance the region’s biotech ecosystem through strategic scouting and investment. This collaboration will focus on identifying promising Israeli technologies, startups, and R&D programs that align with Brazil’s healthcare and pharmaceutical needs. The initiative will also highlight Brazil as an attractive destination for global entrepreneurs and biotech innovators. IBI-Tech and the Peixe Rosa Program will work closely to define commercial terms and implement a framework that fosters investment, innovation, and growth. This partnership will serve as a catalyst for technological advancements, further solidifying Brazil’s position in the global biotech industry while strengthening Israel-Brazil relations in science and medicine.
U.S. Visionary Leadership and Strategic Investments Propel Brazil’s Biopharmaceutical Advancements
This release is a segment of a full release published here. Collaborative Efforts Drive Innovation and Economic Growth The success of the Partnership for Productive Development (PDP) and the Peixe Rosa Program is driven by visionary leadership and a robust financial strategy. Dan BenAmoz, a pioneer in the U.S. pharmaceutical industry, and Nathan BenAmoz, leveraging international connections through CPHI India, have been instrumental in forming this transformative partnership. Their expertise ensures long-term success, global impact, and alignment with international best practices. Supporting this initiative are Mitch Nussbaum, Co-Chair of Loeb and Loeb LLP, providing critical legal consulting, and Dan Nash, Head of Investment Banking at Cohen Capital Markets, contributing advisory expertise in banking, mergers and acquisitions, and strategic planning. Initial discussions with both professionals took place at the 2024 SPAC Conference by Deal Flow Events in New York. To fund this vision, the Peixe Rosa Program is preparing a $1 billion investment fund, supported by foundational agreements with UFPE and public funding. This represents the first phase of a broader $5 billion financial strategy to mobilize resources for infrastructure, technological advancements, and market expansion. These efforts create a launch pad for foreign companies and innovations to enter the Latin American market, pursue U.S. public listings, and ensure substantial financial returns and investor profits. By uniting leadership, investment, and collaboration, the initiative is redefining Brazil’s role in the global biopharmaceutical industry.
Strategic Acquisitions and API Industry Transformation
This release is a segment of a full release published here. Strategic Acquisitions to Revolutionize Brazil’s API Industry To address Brazil’s reliance on imported active pharmaceutical ingredients (APIs), the Partnership for Productive Development (PDP) and the Peixe Rosa Program are exploring transformative acquisitions within the API industry. These strategic moves aim to secure Brazil’s position as a global leader in biopharmaceuticals while enhancing domestic production capabilities. A key acquisition opportunity under discussion could revolutionize the nation’s pharmaceutical landscape, bringing cutting-edge technology, skilled personnel, and immediate capabilities to Brazil. This approach aligns with ongoing discussions between project organizers, the Federal Government in Brasilia, and Brazil’s API association. Wladimir Maia’s involvement with Brazil’s National Cancer Institute underscores the commitment to strategic solutions for API dependency, a pressing issue with national security implications for supply chains. These efforts aim to create a sustainable and resilient pharmaceutical industry.
Peixe Rosa Program: A Vision for Transforming Latin America’s Biopharmaceutical Landscape
This release is a segment of a full release published here. Driving Innovation in Life Sciences Through Research, Collaboration, and Investment Launched in 2016, the Peixe Rosa Program is a transformative initiative designed to bolster Latin America’s biopharmaceutical sector. By integrating a Contract Research Organization (CRO), a Scientific and Technological Park, and plans for an Advanced Center for Translational Medicine, the program is revolutionizing the life sciences industry. Key projects include: Through partnerships with renowned Brazilian institutions, the program attracts substantial foreign investment, aiming to position Brazil as a biopharmaceutical hub. This collaborative vision strengthens access to healthcare while advancing economic growth and global visibility for the region. Note: Featured image is the Sudene building in Pernambuco, Brazil. The building has been provided to support International Companies coming to Brazil under the Peixe Rosa Program.
Transformative Partnership Strengthens Brazil’s Biopharmaceutical Industry and Advances Economic Development
This release is a segment of a full release published here. Uniting Local and Global Expertise to Address Healthcare Challenges and Foster Innovation In a significant step towards revolutionizing Brazil’s healthcare landscape, a new Partnership for Productive Development (PDP) has been announced. This initiative aims to strengthen domestic production of active pharmaceutical ingredients (APIs) and finished medicines, addressing critical healthcare challenges. The ambitious partnership unites Of Joseph PB&T, the Peixe Rosa Program, the Therapeutic Innovation Research Center – Suely Galdino (NUPIT-SG) of the Federal University of Pernambuco (UFPE), with technological contributions from the Indian pharmaceutical industry. Additionally, UNI Pharma API Corp, a U.S.-based investment group, will provide financial backing and support U.S. distribution of excess Brazilian-sourced APIs for finished drug production. Initially focusing on vital leukemia treatments for the Unified Health System (SUS), the project is poised to invest R$84 million in its first phase. This marks a major milestone in advancing the Ministry of Health’s goal to secure robust domestic API manufacturing. Over the next year, three additional PDP initiatives are planned to enhance Brazil’s biotech industrial sector through technology transfer and public investment support. By combining financial expertise, research capabilities, and technological leadership, the collaboration seeks to reduce Brazil’s dependence on foreign suppliers while positioning the nation as a leader in pharmaceutical production and innovation. Cite: Brazil Press on University Initiative to Produce API
